Angiotensin receptor blockers in heart failure: A work in progress

Journal of the American College of Cardiology

Volumn 40, Issue 8, 2002, Pages 1422-1424

  Greenberg, Barry H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; VALSARTAN;

ANGIONEUROTIC EDEMA; CARDIOVASCULAR RISK; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; COUGHING; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG TOLERABILITY; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HUMAN; NOTE; PRESCRIPTION; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0037120935     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(02)02309-4     Document Type: Editorial

References (20)

1. Garg R, Yusuf S, for the Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995;273:1450-6.
2. Braunwald E. ACE inhibitors - a cornerstone of the treatment of heart failure. N Engl J Med 1991;325:351-3.
3. ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction. Circulation 1998;97:2202-12.
4. Latini R, Maggioni AP, Flather M, Sleight P, Tognoni G. ACE inhibitor use in patients with myocardial infarction. Circulation 1995;92:3132-7.
5. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.
6. Husain A. The chymase-angiotensin system in humans. J Hypertens 1993;11:1155-9.
7. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial - the Losartan heart failure survival study ELITE II. Lancet 2000;355:1582-7.
8. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan In The Elderly study, ELITE). Lancet 1997;349:747-52.
9. Goldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systematic hypertension. Am J Cardiol 1995;75:793-5.
10. Lacourciere Y, Brunner H, Irwin R et al and the Losartan Cough Study Group. Effects of modulators of the renin-angiotensin-aldosterone system on cough. J Hypertens 1994;12:1387-93.
11. Cohn JN, Tognini G, for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75.
12. Maggioni AP, Anand I, Gottlieb SO, Latini R, Tognini G, Cohn JN, on behalf of the Val-HeFT Trial Investigators. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 2002;40:1414-21.
13. Feldman AM, Bristow MR, Parmley WM, et al. Effects of vesnarinone on morbidity and mortality in patients with heart failure. N Engl J Med 1993;329:149-55.
14. Cohn JN, Goldstein SO, Greenberg BH, et al. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. N Engl J Med 1998;339:1810-6.
15. Swedberg K, Pfeffer M, Granger C, et al. Candesartan in heart failure - assessment of reduction in mortality and morbidity (CHARM): rationale and design. J Card Fail 1999;5:276-82.
16. Oparil S. Newly emerging pharmacologic differences in angiotensin II receptor blockers. Am J Hypertens 2000;13:185-245.
17. Krämer C, Sunkomat J, Witte J, et al. Angiotensin II receptor - independent antiinflammatory and antiaggregatory properties of losartan: role of the active metabolite EXP3179. Circ Res 2002;90:770-6.
18. 2 -induced platelet aggregation. J Pharmacol Exp Ther 2000;292:238-46.
19. Bart BA, Ertl G, Held P, et al., for the SPICE Investigators. Contemporary management of patients with left ventricular systolic dysfunction: results from the Study of Patients Intolerant of Converting Enzyme inhibitors (SPICE) registry. Eur Heart J 1999;20:1182-90.
20. The Large State Peer Review Organization Consortium. Heart failure treatment with angiotensin-converting enzyme inhibitors in hospitalized Medicare patients in 10 large states. Arch Intern Med 1997;157:1103-8.